Edinburgh, Scotland ( 19 May 2025) - Blackford, the pioneering Enterprise AI platform and solutions provider, and Quibim, a global leader in imaging biomarkers for precision medicine, announced a commercial partnership to bring its flagship product QP-Prostate to healthcare professionals via the Blackford Platform.
Blackford’s proven platform provides healthcare providers with access to a robust portfolio of over 140 AI-driven solutions aimed at enhancing clinical accuracy, streamlining workflows, and improving patient outcomes. Integrated into this ecosystem, Quibim’s QP-Prostate leverages AI to support radiologists by automatically evaluating image quality, segmenting automatically the prostate gland, and identifying suspicious lesions. Designed to optimize radiology workflows, QP-Prostate enables quicker, more accurate assessments—ultimately contributing to more efficient diagnoses and better patient care.
“We’re excited to welcome Quibim and QP-Prostate to the Blackford platform,” says Ben Panter, Founder and CEO of Blackford. “This partnership expands our portfolio with an AI solution that enhances radiology workflows and supports faster, more accurate prostate cancer assessments—helping providers deliver better care with greater efficiency.”
“This partnership marks an important milestone in our mission to advance prostate cancer diagnostics,” said Dr. Ángel Alberich-Bayarri, CEO of Quibim. “Thanks to Blackford’s platform the access to QP-Prostate is being extended, allowing previously unreached radiologists to use AI technology that supports earlier and more accurate detection of clinically significant prostate cancer. As rising incidence rates demand faster and more precise care, this will help streamline MRI interpretation, reduce unnecessary procedures, and better guide treatment decisions, including fusion biopsy and focal therapy.”